2025-05-12 - Analysis Report
## Hims & Hers Health Inc (HIMS) Stock Review

**0. Key Figures Overview:**

HIMS has significantly outperformed the S&P 500 (VOO) over the observed period.  The cumulative return is considerably higher, indicating strong potential, but also higher risk.  Recent price movements show a strong upward trend. Financial statements reveal robust revenue growth and high profit margins, though profitability metrics show some variability.


**1. Performance Comparison & Alpha/Beta Analysis:**

Hims & Hers Health Inc (HIMS) is a telehealth company providing health and wellness products and services.

* **Cumulative Return (HIMS):** 253.51%
* **Cumulative Return (VOO):** 33.53%
* **Return Difference:** 220.0% (This represents a significant outperformance. However, remember that the relative divergence of 83.6% indicates this outperformance is at the high end of its historical range relative to VOO.)

The provided Alpha/Beta analysis shows high volatility and beta, suggesting significant market sensitivity. While the CAGR increased dramatically from 2022-2025, the negative Alphas across all periods suggest that the company has historically underperformed compared to the market after accounting for risk.  The increasing Beta indicates growing sensitivity to market fluctuations.  This is consistent with the high relative divergence observed against the S&P 500.


**2. Recent Price Movement:**

* **Closing Price:** $51.40
* **Last Market Price:** $51.96 (a 1.09 increase from the previous close, indicating a recent upward trend)
* **5-Day Moving Average:** $47.18
* **20-Day Moving Average:** $33.44
* **60-Day Moving Average:** $37.05

The stock price is currently trading above all three moving averages, suggesting a short-term uptrend.

**3. Technical Indicators & Expected Return:**

* **Market Risk Indicator (MRI):** 0.37 (Medium Risk)
* **RSI:** 85.74 (Overbought, suggesting potential for a price correction)
* **PPO:** 8.03 (Positive, indicating upward momentum)
* **Recent (20-day) Relative Divergence Change:** +28.4% (Strong upward momentum)
* **Expected Return:** -7.7% (This is likely a short-term expectation. The long-term (2+ years) expected return relative to the S&P 500 is highly uncertain given the company's high volatility and beta.)  The 2-year + outlook needs to consider the potential for both significant upside and downside.


**4. Recent Earnings Analysis:**

| Date       | EPS  | Revenue       |
|------------|------|---------------|
| 2025-05-05 | $0.22 | $0.59B        |
| 2024-11-04 | $0.35 | $0.40B        |
| 2024-08-05 | $0.06 | $0.32B        |
| 2024-05-06 | $0.05 | $0.28B        |
| 2024-05-05 | $0.05 | $0.28B        |


Revenue shows a clear upward trend, although EPS fluctuates.  Further analysis is needed to understand the drivers behind these fluctuations, including examining operating expenses and potential one-time items. The significant jump in EPS from Q4 2024 to Q1 2025 needs further investigation.


**5. Financial Information:**

**Revenue and Profitability:**

| Quarter     | Revenue | Profit Margin |
|-------------|----------|---------------|
| 2025-03-31  | $0.59B  | 73.50%        |
| 2024-12-31  | $0.48B  | 76.81%        |
| 2024-09-30  | $0.40B  | 79.16%        |
| 2024-06-30  | $0.32B  | 81.30%        |
| 2024-03-31  | $0.28B  | 82.36%        |

**Capital and Profitability:**

| Quarter     | Equity  | ROE     |
|-------------|---------|---------|
| 2025-03-31  | $0.55B  | 9.01%   |
| 2024-12-31  | $0.48B  | 5.46%   |
| 2024-09-30  | $0.44B  | 17.18%  |
| 2024-06-30  | $0.36B  | 3.67%   |
| 2024-03-31  | $0.34B  | 3.23%   |

Revenue demonstrates strong growth. Profit margins are consistently high but show a slight downward trend.  ROE is volatile, highlighting the risk associated with this investment.


**6. Overall Analysis:**

HIMS exhibits strong revenue growth and high profit margins, indicating a potentially successful business model.  However, the high volatility, significant market sensitivity (high Beta), and overbought RSI suggest a high-risk, high-reward investment.  The significant outperformance relative to the S&P 500 is notable but needs to be considered in the context of its high relative divergence and the possibility of a price correction.  The substantial fluctuation in EPS and ROE underscores the need for careful consideration of the company's financial health and future prospects before making any investment decisions.  Further due diligence, including a thorough examination of the company's competitive landscape, management team, and future growth strategy, is strongly recommended.  The recent price increase also warrants caution; the possibility of a pullback should be considered.
